HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on CalciMedica (NASDAQ:CALC) and maintained a $20 price target.
August 13, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on CalciMedica and maintained a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100